Skip to main content

Plaintiffs Ask Merck To Submit Data On Zostavax Vaccine

Plaintiffs Ask Merck To Submit Data On Zostavax Vaccine

Plaintiffs Ask Merck To Submit Data On Zostavax Vaccine

Introduction

According to a motion filed this month, Plaintiff  Executive Committee (PEC) indicated that Merck has refused or delayed to provide adverse reports which include details of injuries, complications, and other negative experiences reported by doctors and patients after receiving the Zostavax vaccine.

The plaintiffs requested the court to force the defendant to turn over the data regarding various Zostavax vaccine problems and to produce their standard operating procedures related to adverse event reports. The opposition response filed by the defendant this week claimed that the plaintiffs’ request was overly broad, arguing that they only had to produce adverse event reports involving the same injuries mentioned in the lawsuits filed till date.

Merck & Co. faces nearly 600 product liability claims, each raising similar allegations that the drugmaker failed to warn about the problems associated with the vaccine which the plaintiffs claim was not sufficient to reduce the reactivation of the dormant virus in some people, resulting in severe and persistent shingles outbreaks, as well as various auto-immune disorders. Zostavax litigation is centralized before U.S. District Judge Harvey Bartle III in the Eastern District of Pennsylvania.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Cencora Directors Settle Opioid Oversight Case for $111M

Categories: Opioids

Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids

Study Finds CPAP May Harm Low-Risk Sleep Apnea Patients

A new study has cast doubt on the long-standing belief that continuous positive airway pressure (CPAP) machines significantly reduce heart…

FDA Adds New Warnings on Long-Term Opioid Risks

Categories: Opioids

Federal regulators have raised concerns that many opioid medications were approved for prolonged use without sufficient clinical evidence confirming their safety.

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!